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Background/aim: Iron deficiency is one of the most common metabolic disorders worldwide and affects multiple organs and systems
including the cardiovascular (CV) system. Iron deficiency can cause structural and functional changes in the myocardium. The aim of
the study is to evaluate left ventricular (LV) functions in patients with low ferritin levels without anemia by two-dimensional “speckle
tracking” echocardiography (2D STE).
Materials and methods: We studied 90 participants (all female) that were divided into two groups according to ferritin levels (49
patients with ferritin levels <30 ng/mL, 41 age-matched controls with >30 ng/mL). Patients with anemia (hemoglobin level <12 g/dL),
known CV disease, diabetes mellitus, low ejection fraction (<55%), active infection, high ferritin levels (>200 ng/mL) were excluded.
All patients were evaluated by transthoracic echocardiography. In addition to conventional echocardiographic parameters and Doppler
measurements, LV global longitudinal strain (GLS) and strain rate (GLSR) were obtained by 2D STE.
Results: Mean ferritin level was 18.96 ± 7.29 ng/mL in low ferritin group, and was 61.22 ± 26.14 ng/mL in control group. There were no
significant differences according to conventional and Doppler echocardiographic parameters between the groups. LV GLS and GLSR
values were significantly lower in low ferritin group comparing with control group (17.31% ± 1.56 and 18.96% ± 1.53, p < 0.001; 0.64 ±
0.13 1/s and 0.81 ± 0.13 1/s, p < 0.001, respectively). There was a significant positive correlation between ferritin levels and LV GLS and
GLSR values in study group (r = 0.482, p < 0.001; r = 0.387, p < 0.001, respectively). Ferritin level was also detected as an independent
risk factor for GLS value < –18% in logistic regression analysis. In ROC curve analysis, the area under the curve for predicting GLS <
–18% was 0.801 (p < 0.001, 95% CI 0.70–0.89) and the threshold of ferritin value was 28.5 ng/mL (sensitivity 76.1%, specificity 77.3%).
Conclusion: Low ferritin levels can cause subclinical LV systolic dysfunction in patients without anemia. STE provides detailed
information about LV functions. With larger studies, these patients should be followed more closely and considered for iron replacement
treatment before developing anemia.
Key words: Iron deficiency, subclinical left ventricular dysfunction, speckle tracking echocardiography, ferritin levels, heart failure

1. Introduction
Iron deficiency (ID) is the most common nutritional
disorder and a major cause of anemia. While the
prevalence of ID is 1%–4% in men and 5%–10% women
in the general population, it is especially common among
menstruating women with a prevalence of 9%–22% [1,2].
Iron is an important micronutrient involved not only in
oxygen transport but also in many metabolic events [3].
A large amount of enzymes in the body requires iron for
their functions. Iron also plays an essential role in cellular
bioenergetics and mitochondrial metabolism.
Iron deficiency is a common comorbidity in patients
with heart failure (HF) with a prevalence of up to 50%
regardless of the presence of anemia and this coexistence

is associated with poor prognosis [4,5]. Despite being such
a common and important public health problem, iron
deficiency is often overlooked and mostly left untreated
unless anemia develops.
Low serum ferritin levels (<30 ng/mL) indicate ID
regardless of anemia and are well known to be associated
with adverse outcomes in patients with HF [6]. Since iron
is an important component of mitochondria, its deficiency
can cause impairment of mitochondrial metabolism in
both skeletal myocytes and cardiomyocytes [7,8]. It has
been shown in animal studies that ID causes structural
changes in the myocardium and cardiac dysfunction [9–
11]. It is thought that there may be a relationship between
low ferritin levels and the development of HF independent
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from anemia and other cardiovascular (CV) risk factors.
Most of the studies investigating the relationship
between ID and cardiac functions have been conducted
in patients with anemia or in patients who already have
had HF. The effect of low ferritin levels on heart functions
in healthy subjects regardless of anemia has not been
adequately studied. Speckle tracking echocardiography
(STE) is a novel method that provides more detailed and
reliable information about LV functions. The aim of this
study is to investigate subclinical LV systolic dysfunction
in childbearing age women with low ferritin levels without
anemia.
2. Methods
2.1. Study population
We studied 90 patients (all female) who applied to the
cardiology outpatient clinics with various symptoms,
whose iron parameters and complete blood count
(CBC) test were required, and who were scheduled for
echocardiography between 2019 and 2021. The patients
were divided into two groups according to their ferritin
levels. While those with ferritin values < 30 ng /mL
constituted the patient group, those with ≥30 ng/mL were
determined as the control group. Patients with anemia
(hemoglobin level < 12 g/dL), known cardiovascular
disease (CVD), more than mild valvular heart disease,
poor echocardiographic image quality, low ejection
fraction (EF) (<55%), atrial fibrillation, and conduction
abnormalities on electrocardiogram (ECG), diabetes
mellitus (DM), active infection, malignancy, high ferritin
levels (>200 ng/mL) and patients who have had iron
replacement therapy or blood transfusion before were
excluded.
Serum ferritin level was measured with
electrochemiluminescence
immunoassay
(ECLIA)
method using the Roche Cobas 6000 (Roche Diagnostics,
Germany).
The study protocol was approved by the Local Ethics
Committee of our institute, and a detailed written
informed consent was obtained from each participant.
The study was conducted according to the Declaration of
Helsinki.
2.2. Echocardiographic assessment
Transthoracic echocardiography was performed in
lateral decubitus position using Epiq 7C ultrasound
system (Philips, Andover, MA, USA) equipped with a
2.3–3.5 MHz transducer probe with simultaneous ECG
recording. Conventional measurements were made on
images obtained from parasternal and apical windows
after adjusting gain and frequency settings following
the recommendations of the American Society of
Echocardiography [12]. Left ventricular ejection fraction
(LVEF) was calculated by the modified two-dimensional

biplane Simpson’s method [13]. LV diastolic function was
evaluated by trans-mitral velocities using pulsed wave
Doppler and mitral annular velocities using tissue Doppler
imaging (TDI).
Standard apical two, three and four chamber images
were recorded over 3 cycles in gray scale with a frame
rate between 60–100 frames/s for two dimensional
speckle tracking echocardiography (2DSTE) assessment.
Offline LV strain analysis was performed using dedicated
software (Qlab advanced quantification software version
10.1, Philips Medical Systems, Bothell, WA, USA). After
tracing LV endocardial border manually at the end of the
systole, the region of interest between endocardium and
epicardium was created automatically by the computer.
If necessary, the width and shape of ROI were adjusted
manually to optimize tracking. Global longitudinal strain
(GLS) and strain rate (GLSR) values were derived by taking
the average of strain measurements obtained at three levels
of six segments from each apical window (Figures 1–4).
3. Statistical analysis
Statistical Package for the Social Sciences 26.0 (SPSS,
Chicago, IL, USA) program was used for the statistical
data analysis. Kolmogorov Smirnov test was applied to
test the normality of the distribution. The results were
presented as means ± standard deviations. Normally
distributed continuous variables were compared using
the Student t-test, and those not, were compared using
Mann Whitney-U test. The chi-square test was used to
compare categorical data. Statistical significance was
defined as p-value less than 0.05. Correlation analyses
were derived by using Pearson analysis for continuous
variables and Spearman’s test for noncontinuous variables
and correlation coefficient (r) was calculated. To evaluate
the effects of various factors on GLS, we performed
multivariate regression analyses using the Logistic
Regression (LR) method. Receiver operating characteristic
(ROC) curve analysis was used to determine the threshold
of the ferritin value to predict LV GLS < –18%.
4. Results
Consecutive 90 female patients were enrolled in the
study and classified into two groups according to ferritin
levels (49 patients with ferritin levels < 30 ng/mL, 41 agematched controls with >30 ng/mL). The demographic
and clinical features of the study groups are presented in
Table 1. The mean ferritin level was 18.96 ± 7.29 ng/mL
in the low ferritin group and was 61.22 ± 26.14 ng/mL in
control group. In addition, in the low ferritin group other
biochemical and blood count parameters related to iron
levels were found to be significantly lower (Table 2). There
were no significant differences according to conventional
and Doppler echocardiographic parameters between the
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Figure 1. Left ventricular apical four-chamber global longitudinal strain imaging
of a patient in low ferritin group.

Figure 2. Left ventricular apical two-chamber global longitudinal strain imaging
of a patient in low ferritin group.

groups. LV GLS and GLSR values were significantly lower
in low ferritin group comparing with controls (–17.31% ±
1.56 and –18.96% ± 1.53, p = 0.0001; 0.64 ± 0.13 and 0.81
± 0.131/s, respectively) (Table 3).
There was significant positive correlation between
ferritin levels and LV GLS and GLSR values in study group
(r = 0.482, p < 0.001; r = 0,387, p < 0.001, respectively).
Ferritin level was also detected as an independent risk
factor for GLS value < –18% in logistic regression analysis
(Table 4). In ROC curve analysis, the area under the curve
for predicting GLS < –18% was 0.801 (p < 0.001, 95% CI
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0.70–0.89) and the threshold of ferritin value was 28.5 ng/
mL (sensitivity 76.1%, specificity 77.3%) (Figure 5).
5. Discussion
The results we obtained in the study revealed that
subclinical impairment of LV systolic function may
develop in young women with low ferritin levels without
anemia and overt CV disease.
The relationship between ID and HF has become the
focus of researchers in recent years. Studies have mostly
investigated the effects of IDA or the outcomes of low iron

CENGİZ ELÇİOĞLU et al. / Turk J Med Sci

Figure 3. Left ventricular apical three-chamber global longitudinal strain
imaging of a patient in low ferritin group.

Figure 4. Left ventricular bull’s eye image of a patient in low ferritin group.

and ferritin levels in HF. Prevalence of iron deficiency in
premenopausal women is approximately 10%–20% and
only 2%–3% of those have anemia [14]. Iron deficiency
can last for years before anemia develops and the diagnosis
may be overlooked especially in asymptomatic individuals.
In clinical practice, unless anemia develops, ID is paid
insufficient attention by most clinicians and cannot
become the main target of the treatment.
Serum ferritin level b
 elow 30 ng/mL is the most sensitive
and specific test for the determination of iron deficiency
[15]. The diagnostic value of ferritin decreases under
conditions such as active infection, chronic inflammatory
disease, and advanced age [16,17]. In a study by Silvestre

et al. investigating the relationship between ferritin levels
and the risk of developing HF, 1063 patients without HF
have been followed for approximately 20 years. Both
high and low ferritin levels have been associated with the
development of new HF [18]. It has been shown in some
animal studies that ID causes impairment in LV function
independent of anemia [9,14]. Rineau et al. demonstrated
in a study conducted on mice that ID without anemia
was associated with reduced exercise capacity and LV
function due to alteration of the mitochondrial function of
cardiomyocytes. In addition, they demonstrated that both
exercise capacity and LV dysfunction are reversed after
iron treatment [10]. In a study by Hoes et al. examining
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Table 1. Demographic and clinical features of the study group.
Parameter

Low ferritin group
(n = 49)

Control group
(n = 41)

p value

Age

35.29 ± 9.05

38.76 ± 9.75

0.084

SBP (mmHg)

109.18 ± 12.22

111 ± 9.99

0.364

DBP (mmHg)

69.39 ± 7.68

71.75 ± 7.8

0.156

Heart rate (beat/m)

75.12 ± 10.15

72.09 ± 6.68

0.106

BSA (m2)

1.67 ± 0.13

1.70 ± 0.21

0.378

Hypertension n (%)

6 (12.2%)

8 (19.5%)

0.343

Hyperlipidemia n (%)

8 (16.3%)

8 (19.5%)

0.694

Smoking n (%)

7 (14.3%)

6 (15%)

0.924

ACEI n (%)

1 (8.2%)

4 (2.5%)

0.248

ARB n (%)

0 (0.0%)

3 (7.5%)

0.051

Beta blocker n (%)

1 (2%)

0 (0.0 %)

0.364

Statin n (%)

2 (4.1%)

0 (0.0%)

0.196

SPB, systolic blood pressure; DBP, diastolic blood pressure; BSA, body surface area; ACEI,
angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Table 2. Biochemical iron and hematologic parameters of the study group.
Parameter

Low ferritin group
(n = 49)

Control group
(n = 41)

p value

Ferritin(ng/mL)

18.96 ± 7.29

61.22 ± 26.14

<0.001

Iron (mcg/dL)

81.22 ± 34.01

99.44 ± 31.58

0.017

IBC(mcg/dL)

358.95 ± 40.17

306.47 ± 41.25

<0.001

Hemoglobin (g/dL)

12.73 ± 0.73

13.22 ± 0.7

0.002

Hematocrit (%)

38.78 ± 2.5

39.84 ± 2.08

0.034

TSAT (%)

22.71 ± 10.39

32.93 ± 11.47

<0.001

WBC count (K/uL)

6.98 ± 1.52

7.27 ± 1.49

0.377

NLR

2.09 ± 0.64

1.86 ± 0.65

0.102

Platelet count(K/uL)

277.23 ± 56.32

257.2 ± 47.09

0.080

IBC, iron binding capacity; TSAT, transferrin saturation; WBC, white blood cell count; NLR, neutrophil
lymphocyte ratio.

the effects of iron deficiency on cardiac functions at the
cellular level, it was shown that human embryonic stem
cell-derived iron-depleted cardiomyocytes had reduced
cellular ATP levels, impaired mitochondrial respiration,
and contractile force. It was also observed that these effects
reversed within three days with transferrin-bound iron
supplementation [19].
The involvement of iron in myocardial metabolism as
a part of oxidative enzymes and mitochondrial respiratory
chain proteins plays a role in the impairment of cardiac
functions even in the absence of anemia. Based on
experimental studies and animal models, the early changes
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caused by iron deficiency in the heart muscle can be
explained by the role of iron in the mitochondrial enzyme
system and collagen synthesis. The decrease in collagen
synthesis due to iron deficiency causes a change in the
pressure-volume relationship with the reduced elasticity
in the myocardium [20]. ID also affects mitochondrial
bioenergetic functions resulting in mitochondrial
swelling in myocardial cells, irregularities in sarcomere
organization, disruption of the cell proliferation cycle,
resulting in cessation of mitosis and apoptosis [21].
Strain analysis with speckle tracking echocardiography
is a method that provides more detailed and accurate
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Table 3. Comparison of echocardiographic measurements of the groups.
Parameter

Low ferritin group
(n = 49)

Control group
(n = 41)

P value

IVS (cm)

0.82 ± 0.06

0.84 ± 0.05

0.068

PW (cm)

0.81 ± 0.05

0.83 ± 0.06

0.063

LVEDD (cm)

4.42 ± 0.2

4.49 ± 0.2

0.131

LVESD (cm)

2.83 ± 0.24

2.88 ± 0.2

0.374

LV EF (%)

61.35 ± 1.67

60.76 ± 1.57

0.091

LA (cm)

3.5 ± 0.17

3.57 ± 0.14

0.068

RA (cm)

3.4 ± 0.17

3.44 ± 0.17

0.302

RV (cm)

3.17 ± 0.2

3.18 ± 0.18

0.913

E wave velocity (cm/s)

89.8 ± 12

82.75 ± 15

0.457

A wave velocity (cm/s)

67.40 ± 16

0.73 ± 0.17

0.229

E/A ratio

1.3 ± 0.37

1.17 ± 0.26

0.173

DT (msn)

168.35 ± 22.11

175.5 ± 28.78

0.825

IVRT (msn)

84.75 ± 6.22

87 ± 6.88

0.131

e’ wave velocity (cm/s)

15.98 ± 2.87

14.81 ± 3.11

0.080

E/e’ ratio

6.17 ± 1.07

6.23 ± 0.82

0.406

GLS (%)

–17.31 ± 1.56

–18.96 ± 1.53

<0.001

GLSR (1/s)

0.64 ± 0.13

0.81 ± 0.13

<0.001

IVS, interventricular septal thickness; PW, posterior wall thickness; LVEDD, left ventricular enddiastolic diameter; LVESD, left ventricular end-systolic diameter; LV EF, left ventricular ejection
fraction; LA, left atrium; RA, right atrium; RV, right ventricle; DT, deceleration time; IVRT, isovolumic
relaxation time; GLS, global longitudinal strain; GLSR, global longitudinal strain rate.
Table 4. Independent risk factors of pathological GLS value in
logistic regression analysis.
Variables

OR (95% C.I)

P

Age

1.0 (0.9–1.1)

0.32

Hypertension

2.2 (0.4–11.6)

0.33

Hyperlipidemia

1.9 (0.3–9.4)

0.42

Smoke

1.5(0.3–7.7)

0.57

Ferritin

0.93 (0.90-0.97)

0.001

information about LV functions and has been used
increasingly in studies and in clinical practice. Although
impairment in left ventricular and atrial functions related
to IDA has been demonstrated in some studies using
STE [22,23], to the best of our knowledge, subclinical
LV dysfunction has not been investigated in patients
with low ferritin levels without anemia. With this study,
we showed low ferritin levels are associated with low LV
global longitudinal strain and strain rate values regardless
of hemoglobin levels in young women. Also, we found a

positive correlation between ferritin levels and LV GLS and
GLSR measurements in the study group. The range of values
considered normal for serum ferritin is quite wide. In this
study the cut-off value of serum ferritin, predicting GLS
value < –18% was found to be 28.5 ng/mL with ROC curve
analysis. Additionally, in logistic regression analysis, low
serum ferritin levels were shown to be an independent risk
factor for LV subclinical dysfunction.
The major limitation of the study was that it included a
small group of patients and was conducted only in women
of childbearing age. This group was chosen because iron
deficiency is a more common and important problem
in young women. The results of the study need to be
validated in different population groups. Since our study
was only observational, whether the patients received iron
replacement therapy afterwards and if they did, the results
were not followed. Also, it was not known how long the
patients were iron deficient.
In conclusion, iron deficiency is a metabolic disorder that
affects large populations around the world. Before anemia
develops, patients may remain undiagnosed for a long time
and cellular morphological and functional abnormalities
that develop during this period may cause subtle myocardial
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impairment before overt cardiac dysfunction occurs.
Regular control of iron parameters becomes important,
especially in young women and symptomatic individuals.
With larger studies also investigating the efficacy of the
treatment on cardiac functions, it may be considered to
follow up iron-deficient patients more closely and with
novel echocardiographic methods and to initiate iron
replacement therapy at an early stage.
Conflict of interest
The study did not get any type of financial support. The
authors declared no conflict of interest.

Figure 5. In receiver operating curve analysis, the area under the
curve for predicting GLS < –18% was 0.801 (p < 0.001, 95% CI
0.70–0.89) and cut-off ferritin value was 28.5 ng/mL (sensitivity
76.1%, specificity 77.3%).

Informed consent
The study protocol was approved by the Local Ethics
Committee of our institute (Koç University Ethical
Committee, IRB No: 2020.016.IRB.007). A detailed written
informed consent was obtained from each participant.
The study was conducted according to the Declaration of
Helsinki.
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